The politics of regulation within the 'modernized' NHS: The case of beta interferon and the 'cost-effective' treatment of multiple sclerosis

Critical Social Policy

Volumn 24, Issue 1, 2004, Pages 30-49

  Crinson, Iain ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Governance; Medicines; NICE; QALYs; Risk sharing

Indexed keywords

COST; DRUG PRESCRIBING; HEALTH SERVICES; MODERNIZATION; REGULATORY APPROACH;

EID: 0742270339     PISSN: 02610183     EISSN: None     Source Type: Journal    
DOI: 10.1177/0261018304241002     Document Type: Article

References (31)

1. Abraham, J. (1995) Science, Politics and the Pharmaceutical Industry. London: UCL Press.
2. Blair, T. (2002) The Courage of our Convictions; Why Reform of the Public Services is the Route to Social Justice. London: The Fabian Society. Edited version in The Guardian, 27 September 2002.
3. Britten, N. (2001) 'Prescribing and the Defence of Clinical Autonomy', Sociology of Health and Illness 23(4): 478-96.
4. Culpitt, I. (1999) Social Policy and Risk. London: Sage.
5. Davis, P. (1997) Managing Medicines: Public Policy and Therapeutic Drugs. Buckingham: Open University Press.
6. Department of Health (1989) Working for Patients. London: HMSO.
7. Department of Health (1992) The Health of the Nation. London: HMSO.
8. Department of Health (1997) The New NHS: Modern, Dependable. London: Stationery Office, Cm 3807.
9. Department of Health (1998) A First Class Service: Quality in the New NHS. London: DoH.
10. Department of Health (1999) Saving Lives: Our Healthier Nation. London: Stationery Office, Cm 4386.
11. Department of Health (2000) The NHS Plan. London: Stationery Office, Cm 4818-1.
12. Department of Health (2002a) Press Release 2002/0328. London: DoH.
13. Department of Health (2002b) Departmental Report 2002. London: DoH.
14. Department of Health (2002c) Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis - HSC 2002/004. London: DoH.
15. Giddens, A. (1991) Modernity and Self-Identity. Cambridge: Polity Press.
16. Giddens, A. (1994) Beyond Left and Right: The Future of Radical Politics. Cambridge: Polity Press.
17. Joyce, P. (2000) 'Governmentality and Risk: Setting Priorities in the New NHS', Sociology of Health and Illness 23(5): 594-614.
18. New, B. (1996) 'The Rationing Agenda in the NHS', British Medical Journal 312: 1593-601.
19. NHS Executive (1995) EL (95) 97 - New Drugs for Multiple Sclerosis. London: DoH.
20. NHS Executive (1998) Executive Summary - Management of the Introduction of Betaferon. London: London Regional Office, DoH.
21. NHS Executive (1999) HSC 1999/176 - NICE: Initial Work Programme. London: DoH.
22. NICE (2000a) Appraisal of the Use of Beta Interferons in the Treatment of Multiple Sclerosis: Decision of the Appeal Panel 22/23 September 2000. London: DoH.
23. NICE (2000b) 'NICE to Commission Further Research on MS Drugs', Press Release 2000/052.
24. NICE (2001) 'Discussions Between the Department of Health and Manufacturers of Beta Interferon', Press Release 2001/034.
25. NICE (2002a) About NICE - Background. [www.nice.org.uk/article.asp] Accessed September 2002.
26. NICE (2002b) Technology Appraisal Guidance No 32 - Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis. London: DoH.
27. NICE (2002c) 'NICE Issues Guidance on Drugs for Multiple Sclerosis', Press Release 2002/007.
28. Paton, C., Birch, K., Hunt, K. and Jordan, K. (1997) 'NHS Reforms: Counting the Costs', Health Service Journal 107(5567): 24-7.
29. Salter, B. (1999) 'Change in the Governance of Medicine: the Politics of Self-Regulation', Politics and Policy 27(2): 143-58.
30. Sudlow, C. and Counsell, C. (2003) 'Problems with UK Government's Risk Sharing Scheme for Assessing Drugs for Multiple Sclerosis', British Medical Journal 326: 388-92.
31. Wanless Report (2001) Securing our Future Health: Taking a Long-Term View - Interim Report. London: HM Treasury.